New integration will improve access to Dario's multi-chronic platform for more people living with diabetes

NEW YORK, Feb. 8, 2023 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO) (the "Company"), a leader in the global digital therapeutics (DTx) market, announced today an agreement with Dexcom (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring (CGM) technology, to integrate its market-leading CGMs, into Dario's multi-chronic condition platform.

Dexcom CGM uses a small, wearable sensor to continuously measure and send glucose levels to a receiver or smart device, enabling people with diabetes to make real-time decisions about their health. This agreement enables the integration of data from Dexcom CGMs directly into Dario's metabolic solution, making it easy for people using the wearable device to benefit from Dario's highly personalized support.

Dario's integrated digital health solution provides highly personalized support for people living with chronic conditions by using clinical, engagement and behavioral data to adapt each user's experience over time. Data from glucose monitoring devices such as Dario's proprietary smart meter and now Dexcom CGMs enable highly personalized journeys that guide users to the most effective and engaging path to better health.

"Nearly two million people use a continuous glucose monitor today, and the ability to capture that data in Dario's platform expands our ability to deliver a dynamic, highly relevant experience to more people living with diabetes. It's an exciting development that will ultimately benefit every Dario member as the CGM data enriches our overall data ecosystem," said Rick Anderson, President of Dario.

The integration with Dexcom builds on the collaboration between Dario and Sanofi US which aims to establish an ecosystem of dedicated technology partners and industry-leading digital therapeutics solutions.

"We're proud of our ongoing collaboration with Sanofi US which is helping Dario to establish new innovations to meet the needs of our customers and members as demonstrated by this Dexcom integration," continued Mr. Anderson.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading digital therapeutics (DTx) company revolutionizing how people with chronic conditions manage their health through a user-centric multi-chronic condition platform. Our platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. 

Our user-centric platform offers people continuous and customized care for health, disrupting the traditional episodic approach to healthcare. This approach empowers people to holistically adapt their lifestyles for sustainable behavior change, driving exceptional user satisfaction, retention, and results. Making the right thing to do the easy thing to do.

Dario provides its highly user rated solutions globally to health plans and other payors, self-insured employers, providers of care and directly to consumers. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses that it sees market demand for integrated solutions continuing to grow and that its multi-chronic solution is answering the great demand for more integrated, more personalized solutions. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Logo - https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg

DarioHealth corporate contact: 
Mary Mooney 
VP Marketing 
mary@dariohealth.com
+1-312-593-4280

Media contact: 
Scott Stachowiak 
scott.stachowiak@russopartnersllc.com
+1-646-942-5630

SOURCE DarioHealth Corp.